Partial review of immunotherapeutic pharmacology in stem cell transplantation

In Vivo

Volumn 14, Issue 1, 2000, Pages 221-236

  Bierman, Philip J ^b   Abe, Fuminori ^c   Buyukberber, Suleyman ^a   Ino, Kazuhiko ^a   Talmadge, James E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c NIPPON KAYAKU CO LTD   (Japan)

Author keywords

Bestatin; BMT; HDT; Hodgkin's disease; Immunomodulator; NHL

Indexed keywords

AMINOPEPTIDASE; BESTATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; HYDROXYUREA; IMMUNOMODULATING AGENT; PHYTOHEMAGGLUTININ; POKEWEED MITOGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE RECONSTITUTION; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; STEM CELL TRANSPLANTATION;

EID: 0034124352     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Kessinger A, Armitage JO, Smith DMj Landmark JD, Bierman PJ and Weisenburger DD: High-dose therapy and autologous peripheral blood stem cell transplantation tor patients with lymphoma. Blood 74: 1260-1265, 1989.
2. Philip T, Armitage JO and Spitzer G: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate- grade or high-grade non-Hodgkin's lymphoma. New England Journal of Medicine 316: 1493-1498, 1987.
3. Phillips GL, Fay JW, Herzig RH, Lazarus HM, Wolf SN, Lin H, Shina DC, Glasgow GP, Griffith RC, Lamb CW and Herzig GP: The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 75: 831-838, 1990.
4. Appelbaum F, Sullivan KM, Buckner CD, Clift R, Deeg HJ, Fefer A, Hill R, Mortimer J, Neiman P, Sanders J, Singer J, Stewart P, Storb R and Thomas ED: Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. Journal of Clinical Onology 5: 9, 1987.
5. Kessinger A, Bierman PJ, Vose JM and Armitage JO: High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 77: 2322-2325, 1991.
6. Freedman AS and Nadler LM: Which patients with relapsed non-Hodgkin's lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? Journal of Clinical Onology 11: 1841-1843, 1993.
7. Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC, Gordon B and Armitage JO: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. Journal of Clinical Onology 11: 1846-1851, 1993.
8. Bishop MR, Anderson JR, Jackson JD, Bierman PJ, Reed EC, Vose JM, Armitage JO, Warkentin Pl and Kessinger A: High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte- macrophage colony- stimulating factor on the autograft. Blood 83: 610-616, 1994.
9. Ager S, Scott MA, Mahendra P, Richards EM, Jestice HK, Boraks P, Baglin TP and Marcus RE: Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: A retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplant 16: 79-83, 1995.
10. Kessinger A: Is blood or bone marrow better? Stem Cells 11: 290-295, 1993.
11. Korbling M and Fliedner TM: The evolution of clinical peripheral blood stem cell transplantation. Bone Marrow Transplant 17: 675-678, 1996.
12. Appelbaum FR: The use of bone marrow and peripheral blood stem cell transplantation in the treatment of cancer [see comments]. CA Cancer J Clin 46: 142-164, 1996.
13. To LB, Haylock DN, Simmons PJ and Juttner CA: The biology and clinical uses of blood stem cells. Blood 89: 2233-2258, 1997.
14. To LB, Roberts MM, Haylock DN, Dyson PG, Branford AL, Thorp D, Ho JQK, Dart GW, Horvath N, Davy ML, Olweny CLM, Abdi E and Juttner CA: Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell trans'plants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 9: 277-284, 1992.
15. Henon PR, Liang H, Beck WG, Eisenmann JC, Lepers M, Wunder E and Kandel G: Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 9: 285-291, 1992.
16. Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, Horning SJ, Brown SL, Miller L and Blume KG: Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81: 2031, 1993.
17. Roberts MM, To LB, Gillis D, Mundy J, Rawling C, Ng K and Juttner CA: Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 12: 469-475, 1993.
18. Verbik DJ, Jackson JD, Pirruccello SJ, Patil KD, Kessinger A and Joshi SS: Functional and phenotypic characterization of human peripheral blood stem cell harvests: A comparative analysis of cells from consecutive collections. Blood 85: 1964-1970, 1995.
19. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T, Lilleby K, Rowley S, Sanders J, Storb R and Buckner CD: Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 88: 2794-2800, 1996.
20. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL, Mills KC, Thomas ML, Pirruccello SJ, Letheby BA, Arneson MA and Jackson JD: Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 17: 101-109, 1996.
21. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW and Grosse Wilde H: Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 88: 2775-2779, 1996.
22. Rosillo MC, Ortuno F, Moraleda JM, Lozano ML, Heras I, De Arriba F and Vicente V: Immune recovery after autologous or rhG-CSF primed PBSC transplantation. Eur J Haematol 56: 301-307, 1996.
23. Talmadge JE, Reed E, Ino K, Kessinger A, Kuszynski C, Heimann D, Varney M, Jackson J, Vose JM and Bierman PJ: Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 19: 161-172, 1997.
24. Mills KC, Gross TG, Varney ML, Heimann DG, Reed EC, Kessinger A and Talmadge JE: Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood. Bone Marrow Transplant 18: 53-61, 1996.
25. Koehne G, Zeller W, Stockschlaeder M and Zander AR: Phenotyp, e of lymphocyte subsets after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 19: 149-156, 1997.
26. Damiani D, Fanin R, Silvestri F, Grimaz S, Infanti L, Geromin A, Cerno M, Michieli M, Rinaldi C, Savignano C, Trani G, Fiacchini M and Baccarani M: Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 90: 36-42, 1997.
27. Janssen WE, Smilee RC and Elfenbein GJ: A prospective randomized trial comparing blood- and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy. Journal of Hematotherapy 4: 139-140, 1995.
28. Weisdorf D, Miller J, Verfaillie C, Burns L, Wagner J, Blazar B, Davies S, Miller W, Hannan P, Steinbuch M, Ramsay N and McGlave P: Cytokine-primed bone marrow stem cells vs. peripheral blood stenl cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF. Biol Blood Marrow Transplant 3: 217-223, 1997.
29. + T-Cell Apoptosis Following Stem Cell. Cancer Research 59: 3107-3111, 1999.
30. Klingemann HG: Introducing graft-versus-leukemia into autologous stem cell transplantation. Journal of Hematotherapy 4: 261-267, 1995.
31. Klingemann HG and Phillips GL: Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 8: 73-81, 1991.
32. Umezawa H, Aoyagi T, Suda H, Hamada M and Takeuchi T: Bestatin, an inhibitor of animopeptidase B, produced by actinomycetes. J Antibiot 29: 97, 1976.
33. Ashmun RA and Look AT: Metalloprotease activity of CD13/aminopeptidase N on the surface of human myeloid cells. Blood 75: 462, 1990.
34. Suda H, Aoyagi T, Takeuchi T and Umezawa H: Inhibition of aminopeptidase B and leucine aminopeptidase by bestatin and its stereoisomer. Arch Biochem Biophys 177: 196-200, 1976.
35. Leyhausen G, Gramzow M, Zahn RK, Steffen R, Umezawa H and Muller WE: Immunochemical identification of the cell surface bound leucine aminopeptidase, the target enzyme for the immunostimulant bestatin. J Antibiot Tokyo 36: 728-734, 1983.
36. Muller WE, Schuster DK, Zahn RK, Maidhof A, Leyhausen G, Falke D, Koren R and Umezawa H: Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells. Int J Immunopharmacol 4: 393-400, 1982.
37. Noma T, Klein B, Cupissol D, Yata J and Serrou B: Increased sensitivity of IL2-dependent cultured T cells and enhancement of in vitro IL2 production by human lymphocytes treated with Bestatin. International Journal of Immunopharmacology 6: 87-92, 1984.
38. Okamura S, Omori F, Haga K, Baba H, Sugimachi K and Niho Y: Influence of bestatin on production of granulocyte-macrophage colony-stimulating factor from human peripheral blood mononuclear cells in vitro. Acta Oncologica 29: 795-797, 1990.
39. Okura A, Ishizuka M and Takeuchi T: Effect of ubenimex on the production of murine interferon. J Antibiot Tokyo 41: 261-263, 1988.
40. Shibuya K, Hayashi E, Abe F, Takahashi K, Horinishi H, Ishizuka M, Takeuchi T and Umezawa H: Enhancement of interleukin 1 and interleukin 2 releases by ubenimex. Journal of Antibiotics 40: 363-369, 1987.
41. Ishizuka M, Sato J, Sugiyama Y, Takeuchi T and Umezawa H: Mitogenic effect of bestatin on lymphocytes. Journal of Antibiotics 33: 653-662, 1980.
42. Talmadge JE, Lenz BF, Pennington R, Long C, Phillips H, Schneider M and Tribble H: Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Research 46: 4505-4510, 1986.
43. Abe F, Hayashi M, Horinishi H, Matsuda A, Ishizuka M and Umezawa H: Enhancement of graft-versus-host reaction and delayed cutaneous hypersensitivity in mice by ubenimex. Journal of Antibiotics 39: 1172-1177, 1986.
44. Jarstrand C and Blomgren H: Influence of Bestatin, a new immunomodulator, on various functions of human monocytes. J Clin Lab Immunol 9: 193-198, 1982.
45. Schorlemmer HU, Bosslet K and Sedlacek HH: The ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes. Cancer Research 43: 4148, 1983.
46. Abe F, Matsuda A, Schneider M and Talmadge JE: Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice. Cancer Immunology and Immunotherapy 32: 75-80, 1990.
47. Aoki I, Higashi K, Nishijima K, Homori M, Chikazawa H and Ishikawa K: Effects of ubenimex on erythroid progenitors (CFU-E and BFU-E) in human bone marrow. Experimental Hematology 19: 893, 1991.
48. Ohhara N, Okamura S, Niho Y and Otsuka T: Stimulatory effect of an aminopeptidase inhibitor on human bone marrow CFU-C mediated by the interaction of T-lymphocytes. Nippon Ketsueki Gakkai Zasshi 48: 1012-1016, 1985.
49. Shibuya K, Chiba S, Hino M, Kitamura T, Miyagawa K, Takaku F and Miyazano K: Enhancing effect of uhenimex (bestatin) on proliferation and differentiation of hematopoietic progenitor cells, and the suppressive effect on proliferation of leukemic cell lines via peptidase regulation. Biomedicine and Pharmacotherapy 45: 71-80, 1991.
50. Abe F, Alvord G, Koyama M, Matsuda A and Talmadge JE: Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases. Cancer Research 28: 29-33, 1989.
51. Abe F, Schneider M, Black PL and Talmadge JE: Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice. Cancer Immunol Immunother 29: 231-236, 1989.
52. Ota k, Kurita S, Yamada K, Masaoka T, Uzuka T and Ogawa N: Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol Immunother 23: 5, 1986.
53. Ota k, Kurita S, Yamada K, Masaoka T, Uzuka Y and Ogawa N: Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol Immunother 23: 5-10, 1986.
54. Urabe A, Mutoh Y, Mizoguchi H, Takaku F and Ogawa N: Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Ann Hematol 67: 63-66, 1993.
55. Hiraoka A, Shibata H and Masaoka T: Study Group of Ubenimex for BMT, Immunopotentiation with ubenimex for prevention of leukemia relapse after allogeneic BMT. Transplant Proc 3047, 1992.
56. Ino K, Singh RK and Talmadge JE: Monocytes from mobilized stem cells inhibit T cell function. Journal of Leukocyte Biology 61: 583-591, 1997.
57. Badger AM, King AG, Talmadge JE, Schwartz DA, Picker DH, Mirabelli CK and Hanna H: Induction of non-specific suppressor cells by a novel azaspirane, SK&F 105685, an immunomodulatory compound with therapeutic activity in animal models of autoimmune disease. Journal of Autoimmunity 3: 485-500, 1990.
58. Roux E, Helg C, Dumont Girard F, Chapuis B, Jeannet M and Roosnek E: Analysis of T- cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T- cell depleted and unmanipulated grafts. Blood 87: 3984-3992, 1996.
59. Storek J, Witherspoon RP and Storb R: T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 16: 413-425, 1995.
60. + T-lymphocyte regeneration after intensive chemotherapy. New England Journal of Medicine 332: 143-149, 1995.
61. Stutman O: Post-thymic T-cell development. Immunological Reviews 91: 159-194, 1986.
62. + cells in adhesion molecule expression. Bone Marrow Transplant 19: 1175-1181, 1997.
63. Sugiura K, Ikehara S, Inaba M, Haraguchi S, Ogata H, Sargina EE, Sugawara M, Ohta Y and Good RA: Enrichment of murine bone marrow natural suppressor activity in the fraction of hematopoietic progenitors with interleukin 3 receptor-associated antigen. Experimental Hematology 20: 256-263, 1992.
64. Young MRI, Young ME and Wright MA: Stimulation of immune-suppressive bone marrow cells by colony-stimulating factors. Experimental Hematology 18: 806-811, 1990.
65. Oghiso Y, Yamada Y, Ando K, Ishihara H and Shibata Y: Differential induction of prostaglandin E2-dependent and - independent immune suppressor cells by tumor-derived GM-CSF and M-CSF. Journal of Leukocyte Biology 53: 86, 1993.
66. Ageitos AG, Singh RK, Ino K, Ozerol I, Tarantolo S, Reed EK and Talmadge JE: IL-2 Expansion of T and NK Cells from Growth Factor-Mobilized Peripheral Blood Stem Cell Products: Monocyte Inhibition. Journal of Immunotherapy 21: 409-417, 1997.
67. Ozerol I, Ageitos A, Heimann D and Talmadge JE: Impaired T and NK Cell Response of Bone Marrow and Peripheral Blood Stem Cell Products to, Interleukin (IL)-2. Int J Immunopharmacol in press: 1999.
68. + cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 89: 1629-1634, 1997.
69. Tanaka J, Mielcarek M and Torok-Storb B.: Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood 91: 347-352, 1998.
70. Ino K, Bierman PJ, Varney ML, Heimann DG, Kuszynski CA, Walker SA and Talmadge JE: Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation. Cancer Immunol Immunother 43: 206-212, 1996.
71. Talmadge JE, Ino K, Bierman PJ: Bestatin for anticancer treatments. Kimball ES. ImmunoPharmaceuticals, Boca Raton: CRC Press: 1995, p. 135.
72. Talmadge JE: The combination of stem cell transplantation and immunotherapy: Future potential. In Vivo 8: 675-690, 1994.
73. Koyama M: Pharmacokinetics and Biotransformation of Bestatin. Umezawa H. Recent Results of Bestatin.Jpn Antibiot Res Assoc. Tokyo: 1987, p.p. 41.